# Medinoah

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medinoah

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.medinoah.com
- Total disclosed funding: $30M
- Latest round: Series B (Mar 30, 2023)
- Investors on record: 7

## About

Established in 2008 and based in Suzhou, China, Medinoah operates as a complex chemical drugs developer that provides drug synthesis, screening and structure optimization, and production process development. In May 2021, it raised approximately CNY 100 million in series A funding led by Suzhou Zhongxin Innovation Investment Management. In October 2021, Hefei High-tech Zone Management Committee became the strategic partner of the company. In February 2022, the company established Hefei R&D center. Shandong Longchen Pharmaceutical Co., Ltd. is the subsidiary of the company. Yanong Wang is the CEO of the company, and he once served as the chief scientist and project leader of Wyeth Corporation of USA. The core research team has master's degree.

The company mainly provides services include drug synthesis, screening and structural optimization, process development, analytical development and quality control, and cGMP production. Its products is divided into three series, which include drug impurity standards, chiral intermediates and pharmaceutical intermediates and API. It has many clients, such Celgene, Arvinas, BeBetter Med, etc. The company also provides CRO service, CDMO and CMC services. CRO service includes FTE services, custom synthesis, specialty chemical synthesis and pharmaceutical intermediates library. CDMO and CMC services include API CDMO services, chemical formulation services, CMO pilot and commercial manufacturing services, CMC services and registration support. Its equipment includes nuclear magnetic resonance (NMR), triple quadrupole liquid phase tandem mass spectrometer (LC-MS-MS) and gas chromatography-mass spectrometer (GC-MS).

## Funding rounds

- Series B, Mar 30, 2023, $15M — Oriza Holdings, Addor Capital, Hankang Capital
- Series A, Jun 22, 2021, $15M — Oriza Holdings, Dynamic Capital, Huiyi Capital, Honest Capital, Zhongxin Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series A
- Huiyi Capital (https://capitalatlas.ai/funds/huiyi-capital) — Series A
- Honest Capital (https://capitalatlas.ai/funds/honest-capital) — Series A
- Zhongxin Capital — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series B